Alterations in drug disposition during pregnancy: implications for drug therapy
LS Hodge, TS Tracy - Expert opinion on drug metabolism & …, 2007 - Taylor & Francis
The disposition of many medications is altered during pregnancy. Due to changes in many
physiological parameters as well as variability in the activity of maternal drug-metabolizing …
physiological parameters as well as variability in the activity of maternal drug-metabolizing …
TGF-β upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma
…, B Xiu, SC Ziesmer, TL Price-Troska, LS Hodge… - Leukemia, 2014 - nature.com
Transforming growth factor beta (TGF-β) has an important role in mediating T-cell suppression
in B-cell non-Hodgkin lymphoma (NHL). However, the underlying mechanism responsible …
in B-cell non-Hodgkin lymphoma (NHL). However, the underlying mechanism responsible …
[HTML][HTML] Multidisciplinary model to implement pharmacogenomics at the point of care
PJ Caraballo, LS Hodge, SJ Bielinski, AK Stewart… - Genetics in …, 2017 - nature.com
Purpose: Despite potential clinical benefits, implementation of pharmacogenomics (PGx)
faces many technical and clinical challenges. These challenges can be overcome with a …
faces many technical and clinical challenges. These challenges can be overcome with a …
Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity
…, SC Ziesmer, LL Almada, LS Hodge… - Blood, The Journal …, 2011 - ashpublications.org
Although proinflammatory and chemotactic cytokines can profoundly affect the tumor
microenvironment, and many of them have been shown to have therapeutic efficacy in preclinical …
microenvironment, and many of them have been shown to have therapeutic efficacy in preclinical …
[HTML][HTML] Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma
Lack of remission or early relapse remains a major clinical issue in diffuse large B-cell
lymphoma (DLBCL), with 30% of patients failing standard of care. Although clinical factors and …
lymphoma (DLBCL), with 30% of patients failing standard of care. Although clinical factors and …
Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma
PR Marri, LS Hodge, MJ Maurer, SC Ziesmer… - Clinical cancer …, 2013 - AACR
… Hodge … PR Marri and LS Hodge contributed equally to this work. … Writing, review, and/or
revision of the manuscript: PR Marri, LS Hodge, MJ Maurer, SL Slager, TM Habermann, BK Link, …
revision of the manuscript: PR Marri, LS Hodge, MJ Maurer, SL Slager, TM Habermann, BK Link, …
[HTML][HTML] Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
SM Ansell, LS Hodge, FJ Secreto, M Manske… - Blood cancer …, 2014 - nature.com
Massively parallel sequencing analyses have revealed a common mutation within the MYD88
gene (MYD88 L265P) occurring at high frequencies in many non-Hodgkin lymphomas (…
gene (MYD88 L265P) occurring at high frequencies in many non-Hodgkin lymphomas (…
[HTML][HTML] Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma
…, SC Ziesmer, B Xiu, NR Yates, FJ Secreto, LS Hodge… - PloS one, 2013 - journals.plos.org
While the effect of TGF-β on malignant B cells in non-Hodgkin lymphoma (NHL) has been
previously evaluated, studies to specifically define the role of TGF-β in tumor immunity in B-cell …
previously evaluated, studies to specifically define the role of TGF-β in tumor immunity in B-cell …
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia
LS Hodge, SC Ziesmer, ZZ Yang… - Blood, The Journal …, 2012 - ashpublications.org
Cytokines within the tumor microenvironment play an important role in supporting the growth
and survival of B-cell malignancies. One such cytokine, IL-21, promotes the growth of …
and survival of B-cell malignancies. One such cytokine, IL-21, promotes the growth of …
Establishment and characterization of a novel Waldenström macroglobulinemia cell line, MWCL-1
LS Hodge, AJ Novak, DM Grote… - Blood, The Journal …, 2011 - ashpublications.org
… Total RNA was isolated using Trizol LS reagent (Invitrogen) as per the manufacturer's
instructions, and RNA was reverse transcribed with Superscript III Reverse Transcriptase (…
instructions, and RNA was reverse transcribed with Superscript III Reverse Transcriptase (…